Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) EBIT Margin (2020 - 2023)

Historic EBIT Margin for Gain Therapeutics (GANX) over the last 4 years, with Q1 2023 value amounting to 9477.68%.

  • Gain Therapeutics' EBIT Margin fell 21709300.0% to 9477.68% in Q1 2023 from the same period last year, while for Dec 2023 it was 40328.26%, marking a year-over-year decrease of 276401600.0%. This contributed to the annual value of 40328.26% for FY2023, which is 276401600.0% down from last year.
  • Latest data reveals that Gain Therapeutics reported EBIT Margin of 9477.68% as of Q1 2023, which was down 21709300.0% from 5442.98% recorded in Q2 2022.
  • Gain Therapeutics' 5-year EBIT Margin high stood at 3941.29% for Q2 2021, and its period low was 46819.42% during Q1 2021.
  • For the 4-year period, Gain Therapeutics' EBIT Margin averaged around 13028.23%, with its median value being 8355.01% (2020).
  • In the last 5 years, Gain Therapeutics' EBIT Margin tumbled by -391428100bps in 2021 and then soared by 395126600bps in 2022.
  • Gain Therapeutics' EBIT Margin (Quarter) stood at 17678.47% in 2020, then soared by 58bps to 7426.33% in 2021, then increased by 27bps to 5442.98% in 2022, then crashed by -74bps to 9477.68% in 2023.
  • Its last three reported values are 9477.68% in Q1 2023, 5442.98% for Q2 2022, and 7306.75% during Q1 2022.